Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)

Inclusion Criteria: * Negative clinical history for varicella, herpes zoster, measles, mumps, and rubella Exclusion Criteria: * Received any measles, mumps, rubella, or varicella vaccine at any time prior to the study, or is anticipated to receive any of these vaccines outside the study * Any congenital or acquired immune deficiency, neoplastic disease, or depressed immunity * Received systemic immunomodulatory steroids within 3 months prior to entering the study or is expected to receive them during the course of the study * History of allergy or anaphylactic reaction to neomycin, gelatin, sorbitol, egg proteins, chicken proteins, or any component of VARIVAX™ or M-M-R II™ * Received salicylates within 14 days prior to study vaccination * Exposed to varicella, herpes zoster, measles, mumps, or rubella in the 4 weeks prior to study vaccination * Received immune globulin, a blood transfusion, or blood-derived products within 5 months prior to study vaccination * History of seizure disorder, including febrile seizure * Fever illness (\>=102.2 °F \[39.0 °C\] within 72 hours prior to study vaccination * History of thrombocytopenia * Born to a human immunodeficiency virus (HIV)-infected mother * Participated in any other clinical trial (other than a surveillance study) within 30 days prior to study enrollment.